InflaRx N.V. Stock News

Gainers AVEO Pharmaceuticals (NASDAQ: AVEO) shares are trading higher after the company announced the submission of a new drug application to the FDA for Tivozanib in...

InflaRx N.V. (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the enrollment of the first patient into a

InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the...

Gainers • Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) stock surged 104.67% to $8.33 during Tuesday's pre-market session. • Owens & Minor, Inc. (NYSE:OMI) stock...

Inflarx NV (NASDAQ:IFRX)’s stock price fell 13.6% during trading on Wednesday . The company traded as low as $3.18 and last traded at $3.23, 755,400 shares were traded during mid-day trading. An inc

Inflarx NV (NASDAQ:IFRX) has earned a consensus rating of “Hold” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the

“A volatile, risk-off environment could make these relative outperformers,” writes Jeffries’ Michael Yee.

Inflarx NV (NASDAQ:IFRX)’s stock price fell 8% on Thursday . The company traded as low as $4.06 and last traded at $4.16, 671,000 shares were traded during mid-day trading. An increase of 13% from t

Spherix (NASDAQ:SPEX) -25%.Dynatronics (NASDAQ:DYNT) -22%.China Pharma Holdings (NYSEMKT:CPHI) -19%.Co-Diagnostics (NASDAQ:CODX) -17%.Tilray (NASDAQ:TLRY) -14% on Q4 earnings.Cleveland BioLabs (NAS

The top-ranked sectors are healthcare, utilities, and technology. Services are neutral.

Inflarx (NASDAQ:IFRX) was upgraded by research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday, ValuEngine reports. Separately, Zacks

SELLAS Life Sciences Group (NASDAQ:SLS) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia.Alcon (NYSE:ALC) +10% on Q4 results.Moderna (NASDAQ:MRNA) +9%�

Gainers Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) stock moved upwards by 65.7% to $0.67 during Wednesday's pre-market session. InflaRx, Inc. (NASDAQ: IFRX) stock...

InflaRx to present initial data at the SVB Leerink Global Healthcare Conference today at 9:00 am EST (3:00 pm CET). JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a clinical-

JENA, Germany, Feb. 19, 2020 -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement.